Korean J Med.  2012 Oct;83(4):520-524.

Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report

Affiliations
  • 1Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea. avnrt@hanmail.net

Abstract

Everolimus, an inhibitor of the mammalian target of rapamycin, is an active agent against metastatic renal cell carcinoma. Treatment with everolimus prolongs progression-free survival in patients with clear cell-type renal cell carcinoma that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitors, such as sunitinib and/or sorafenib. Everolimus-induced interstitial pneumonitis is not rare and is sometimes fatal. Due to the potential for pulmonary toxicity due to everolimus, it is recommended that pulmonary complications be periodically evaluated. We report a case of everolimus-associated interstitial pneumonitis in a patient with metastatic renal cell carcinoma.

Keyword

Clear cell metastatic renal cell carcinoma; Everolimus; Interstitial pneumonitis

MeSH Terms

Carcinoma, Renal Cell
Disease-Free Survival
Humans
Indoles
Lung Diseases, Interstitial
Niacinamide
Phenylurea Compounds
Protein-Tyrosine Kinases
Pyrroles
Receptors, Vascular Endothelial Growth Factor
Sirolimus
Everolimus
Indoles
Niacinamide
Phenylurea Compounds
Protein-Tyrosine Kinases
Pyrroles
Receptors, Vascular Endothelial Growth Factor
Sirolimus
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error